Effects of human umbilical cord blood mononuclear cells on respiratory system mechanics in a murine model of neonatal lung injury

Abstract

These results suggest that cord blood MNCs may have a cell type-specific role in therapy of pulmonary conditions characterized by increased airway resistance, such as BPD and asthma. Future studies need to determine the active MNC subtype(s), their mechanisms of action, and optimal purification methods to minimize granular cell contamination.

Umbilical Cord Blood Cells Do Not Reduce Ventilation-Induced Lung Injury in Preterm Lambs

“…One promising source of stem cells is umbilical cord blood (UCB), which is usually discarded at birth and is an abundant source of stem and progenitor cells. Studies using both UCB mononuclear cells and individual cell types found within UCB have shown promising results in the attenuation of lung injury following hyperoxia (Mills et al, 2017;Monz et al, 2013). Further, individual UCB cell types have reduced lung injury in various experimental models including mesenchymal stem cells (MSCs) (Chang et al, 2009), T regulatory cells (Tregs) (Garibaldi et al, 2013), and hematopoietic stem cells (De Paepe et al, 2011;Huang et al, 2014).…”

Are all stem cells equal? Systematic review, evidence map, and meta-analyses of preclinical stem cell-based therapies for bronchopulmonary dysplasia

“…Yet there has been no systematic review to assess the extent of current evidence regarding safety and efficacy of cell-based therapies in preclinical BPD and identify gaps that could jeopardize successful clinical translation. studies), [26][27][28][29]32,34,35,37,39,40,42,43,48,49,[51][52][53][55][56][57][58][59][61][62][63]66,[68][69][70]72,73,[75][76][77][78] human amniotic epithelial cells (hAEC, n = 4), 36,64,65,74 mononuclear CD34 + (n = 4), 27,30,46,47 endothelial colony forming cells (ECFC, n = 3), 46,64,70 endothelial progenitor cells (EPCs, n = 3), 31,41,71 bone marrow derived angiogenic cells (BMDAC, n = 1), 71 bone marrow derived (BM) ckit+ cells (n = 1), 50 cord blood CD34 + (n = 1), 44 human amniotic fluid stem cells (hAFSC, n = 1), 33 human-induced pluripotent...…”

“…53 In contrast, fewer "Cell-free" therapies were investigated, and these included MSC-derived conditioned media (CdM, n = 6), 34,35,48,49,56,66 ECFC-Conditioned media (CdM, n = 2), 38,60 or MSC-derived exosomes (n = 1). 67 The control groups were most often treated with saline (n = 32) [26][27][28][29][30][31][32]34,37,40,44,46,47,49,51,52,[56][57][58][59]61,62,64,65,[68][69][70][71][72][74][75][76][77] or with a control cell/ cell-free media (n = 12). 33,35,46,[48][49][50]53,…”

“…67 The control groups were most often treated with saline (n = 32) [26][27][28][29][30][31][32]34,37,40,44,46,47,49,51,52,[56][57][58][59]61,62,64,65,[68][69][70][71][72][74][75][76][77] or with a control cell/ cell-free media (n = 12). 33,35,46,[48][49][50]53,60,63,66,67,78 Rarely, the control would receive no treatment (sham control) (n = 2). 36,39…”

“…Supplemental ECFC, 38 EPC, 31,41 BMDAC, 71 hAEC, 36,74 hAFSC, 33 hiPSC-derived LPC, 53 and hiPSC-derived AEC. 53 Different from this were "probably beneficial" therapies which included ECFC, 60 hAEC, 60,64,65 CB CD 34+, 44 Mononuclear CD 34+, 46,47 and BM Ckit+. 50 MSCs (intranasal route) 32 and one with embryonic EPC, 71 concluded that these therapies were not effective.…”